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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrotic interstitial lung disease of unknown origin. It
has a median survival of three years but a wide range in survival rate which is difficult to predict at the time of
diagnosis. Specialist guidance promotes a patient centred approach emphasising regular assessment, information
giving and supportive care coordinated by a multidisciplinary team (MDT). However understanding of patient
and carer experience across the disease trajectory is limited and detailed guidance for MDTs on communication,
assessment, and triggers for supportive and palliative interventions is lacking. This study addresses uncertainties
relating to care needs of patients and carers at different stages of the IPF disease trajectory.
Methods: Following ethical approval a multi-centre mixed-methods study recruited participants with IPF at four
stages of the disease trajectory. Qualitative analysis was used to analyse 48 semi-structured interviews with
patients (27) and paired carers (21).
Results: Patients and carers outlined key elements of MDT activity capable of having significant impact on the
care experience. These were structured around:
 Focus of clinical encounters
 Timely identification of changes in health status and functional activity
 Understanding of symptoms and medical interventions
 Coping strategies and carer roles.
Conclusions: Patients diagnosed with IPF have a clear understanding of their prognosis but little understanding
of how their disease will progress and how it will be managed. In depth analysis of the experiences of patients
and carers offers guidance for refining IPF clinical pathways. This will support patients and carers at key transition
points in line with National Institute for Health and Care Excellence (NICE) guidance.
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Background
Idiopathic pulmonary fibrosis (IPF) is a progressive, life-
limiting condition thought to arise from aberrant would
healing following repeated alveolar microinjury, resulting
in progressive lung fibrosis [1]. Epidemiological evidence
suggests IPF incidence is rising by 5 % per annum in the
UK, with over 4000 new cases and 3000 deaths each year
[2, 3]. Whilst median survival for people with IPF is
about three years, its clinical course is variable; in some
patients lung function deteriorates slowly whilst others
have a rapidly progressive course and occasional patients
experience a particularly fulminant acute exacerbation
resulting in precipitous decline [4]. Furthermore, at the
time of diagnosis, it is difficult to accurately predict an
individual’s disease trajectory leaving patients with an
uncertain future.
There are few parameters that will accurately predict
rate of decline at the time of diagnosis and the only
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therapy that improves survival is lung transplantation in
eligible candidates.
Patients with IPF describe reduced health status, high
symptom burden and impaired quality of life [5, 6]. They
have a twofold higher use of inpatient and outpatient
resources compared to the background population, and
higher direct medical costs [7]. There are few interven-
tions known to improve functional or symptomatic out-
comes and a lack of consensus as to what outcome
measures are important in clinical practice and research
[8, 9]. Current guidance promotes a patient and carer
centred, supportive approach coordinated by a multidis-
ciplinary team with appropriate skill mix [10–12]. How-
ever, most research to date has focused on disease
modification measured by respiratory function tests, with
limited objective information on the wider impact of IPF
on daily life. Furthermore, our understanding of patient
and carer experience across the varied disease trajectories
is limited, and there is no detailed guidance for MDTs on
communication, assessing the need for supportive and
palliative interventions, and identifying the triggers which
should initiate them as the disease progresses.
Qualitative research provides rich data, giving insight
into how people make sense of their experiences and
helping elucidate complex settings and interactions. It
plays an increasingly important role in health service
research and is particularly helpful in understanding the
supportive role of carers, whose perspective may not be
appreciated in the clinical setting [13–16]. A small num-
ber of important qualitative studies of IPF have explored
aspects of patient quality of life and experience of illness
[17–19], but these have not compared patients at differ-
ent stages of disease and there is little information on
the experiences and needs of carers.
This study was designed to explore the perspectives of
patients and their carers across the IPF spectrum to
inform the development of clinical pathways and multi-
disciplinary service interventions as described in Table 1.
Methods
Study design
The uncertain nature of disease progression in IPF
makes a longitudinal study difficult to achieve in a set
time frame. Therefore, we chose a cross-sectional, mixed
method design to study patients at different stages of
IPF and matched carers. Specialists with expertise in
palliative care and interstitial lung disease, who were
part of the research team, generated a disease typology
to classify patients into four stages of IPF described in
Table 2. Patients were categorized according to disease
extent: limited or extensive, and also disease behaviour:
stable or progressive. This produced the four representa-
tive trajectories, for example limited stable or extensive
progressive.
An experienced qualitative researcher (CS) conducted
semi-structured interviews with participants and per-
formed an initial analysis, using Interpretative Phenom-
enological Analysis (IPA). Emerging results were verified
by other members of the research team. In keeping with
recommendations for IPA, we aimed for a sample size of
6–10 patients and 6–10 carers per group, representing a
perspective rather than a population. Consolidated criteria
for reporting qualitative research (COREQ) guidelines
were followed [20].
The study gained favourable opinion, 20/04/2012,
from the South East Wales Research Ethics Committee,
Panel B, 12/WA/0109 prior to the study commencing.
The sponsor was Cardiff University (SPON 1088-12).
Recruitment
Twenty seven patients with IPF and twenty one matched
carers were recruited from two UK specialist interstitial lung
disease clinics between October 2012 and August 2014. Pa-
tients were included if they met the American Thoracic So-
ciety criteria for IPF diagnosis [11]. No patients had been
prescribed pirfenidone. Patients who did not have a carer,
but who wished to participate, were included. A carer was
defined as a person of the patient’s choice who contributed
most to their care or, in the earlier stages of disease, pro-
vided emotional support. They were recruited after patients’
agreement and gave written informed consent. Exclusion
criteria for participants were factors preventing communica-
tion, comprehension of study information or providing in-
formed consent. Of the 27 patients 18 were male and 9
female with 6 male carers and 15 female carers. There were
3 male patients living alone and 2 female patients.
Analysis
Anonymised transcripts were analysed by the qualitative
researcher (CS) to capture patients and carer themes as
described in Table 3. Analysis is described in detail in
the online Additional file 1: Appendix. Table 4 outlines
the analysis framework.
Results
Patients reported that their overall experience of living
with IPF was one of coming to terms with a complex
condition requiring a complicated and often protracted
diagnostic work-up, with an uncertain but limited prog-
nosis. They felt they received insufficient information on
the clinical and practical management of their disease
and would have welcomed more advice on pragmatic
interventions at key points to help manage an unpredict-
able future. Although several common themes emerged
for all patients, there was evidence of variation in the im-
pact of IPF on patients from different disease trajectories.
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Additional file 2: Box 1 summarises the key themes,
common to patients and carers from all four trajectories,
where IPF had significant impact on daily life.
Communication and information
Communication skills
Patients and carers reported that their key needs were
structured around context, timing, content and format
of information. They described a need to balance hon-
esty and hope, whilst dealing with a terminal prognosis
but searched for positive ways to manage and live with
an uncertain disease trajectory (Additional file 3: Box 2).
Context
The specialist IPF clinic was seen as a trustworthy
source of information. However, focus of the consult-
ation was often perceived as disconnected from partici-
pants’ experience of the disease and its impact on
everyday life. They felt unable to interpret the relevance
of disease-focused assessments such as lung function
tests to future exercise capacity or overall prognosis
(Additional file 4: Box 3). Carers felt their role in clinical
consultations was ambiguous and passive and this com-
pounded the difficulty of accessing and interpreting informa-
tion. Carer needs for independent information and advice
were overshadowed by their desire to avoid distress to their
partners in the clinic setting. Outside the specialist clinic the
relative lack of knowledge about IPF in Primary Care
added to the burden of uncertainty about future
management.
Timing
The complexity of the diagnostic process often resulted
in prolonged investigations and delays in referral to the
appropriate specialist. Initial relief that the diagnosis was
not cancer was replaced by shock at the likely prognosis.
Patients and carers in the Limited Stable trajectory in
particular struggled with uncertainties around the pos-
sible course of IPF. Their need to receive information at
an appropriate pace triggered by changes they perceived
in health status didn’t always coincide with the timing of
clinic appointments. Paradoxically, they recalled feeling
greatest concern about attending clinics where they had
observed fellow patients with more severe IPF.
The specialist nurse was perceived as a key resource,
enabling patients and carers to access help on practical
management and triggering medical intervention when
required. Despite this, patients and carers still struggled
with uncertainty around key turning points if they
occurred between clinic visits.
Content and format
Patients and carers appeared to show a good under-
standing of the overall prognosis for IPF but had diffi-
culty translating this to their own particular disease
progression and the management/support options
available to them. They declared a need for specific in-
formation relating to oxygen therapy, nutrition, exer-
cise, management of cough and breathlessness and
disease management towards the end of life. Patients
living alone were most direct in their need for infor-
mation about future care planning.
Table 1 Specific objectives of the CaNoPy study
1. Describe changes in individuals’ and carers’ perceived care needs at
different stages of IPF in order to improve future service interventions
2. Identify time points or triggers at which supportive and palliative care
services might effectively be introduced
3. Define what information individuals with IPF and their carers require
over time
4. Evaluate the experiences and roles of carers for people with IPF





vital capacity (FVC) greater
than 50 % predicted and
gas transfer (TLCO) greater
than 40 % predicted
Extensive disease: FVC less
than 50 % or TLCO less




Stable disease: a decline
of less than 10 % in FVC
or less than 15 % in TLCO
in the previous 12 months
Progressive disease: a
decline in either FVC greater
than 10 % or TLCO greater
than 15 % during the
previous 12 months








Extensive Progressive 69.5 56–77 2 F 1 M 1 3
Limited Progressive 72.6 59–81 2 F 3 M 1 0
Extensive Stable 71 69–82 2 F 4 M 0 2
Limited Stable 75.1 66–87 3 F 6 M 0 0
Table 4 Interpretative phenomenological analysis framework
• Initial reading
Reading of first transcript line-by-line, with preliminary comments
• Early analysis
Comments grouped into themes
• Higher level abstraction
Relationships developed between themes leading to an organised
master list and thematic account of the case
• Subsequent transcripts
New themes tested against the previous transcripts as non-recurring
themes were tested against following transcripts. Relationships across
cases noted to identify a set of superordinate themes for the group
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Written information was most often suggested as
useful. The internet was sometimes cited as portraying
‘worst case scenarios’ and there were mixed responses to
the utility of a peer support group.
Changes in health status
Monitoring disease progression
As patients and carers had difficulty interpreting object-
ive, clinic-based disease assessments, they described how
they developed their own subjective strategies for moni-
toring IPF. These included looking for clues to health
status by observing alterations to the frequency of clinic
appointments and comparison with other patients en-
countered in the clinic or support groups. They also as-
sociated deterioration of IPF with intercurrent illnesses
such as chest infections, initiation or increased use of
use of oxygen, and changes in functional activity (Add-
itional file 5: Box 4).
Negotiating disease progression
Sustained deterioration in health status led subjects to re-
evaluate the uncertainty of their future (Additional file 6:
Box 5). For those in the progressive trajectories, these
shifts were associated with emerging differences in the in-
formation needs and coping styles of their carers who
sought frank, objective information about functional de-
terioration and prognosis to help plan future care. This
contrasted with patient reluctance to receive such detailed
information. Perhaps unsurprisingly, the clinic environ-
ment struggled to meet these differing needs.
Functional activity
Diminished possibilities
Deterioration in health increased risk of social isolation for
patients and carers, who experienced loss in relinquishing
valued activities and responsibilities. Both groups adapted
to a lifestyle of gradually declining choices rather than seek-
ing assistance to optimise their functional activities (Add-
itional file 7: Box 6). This was particularly apparent in
patients living alone.
Most patients and carers felt unable to identify poten-
tial sources of help due to their uncertainty about the
IPF course. Declining health status increased the emo-
tional and domestic burden on carers, while patients
expressed fears about employment loss, finance and how
their partner would cope in future.
Understanding of symptoms and medical interventions
Specific concerns
There were specific concerns, especially for carers, re-
garding symptom monitoring in relation to breathing,
cough and use of oxygen. Differing expectations between
patients and carers were particularly evident around
oxygen use (Additional file 8: Box 7). Carers viewed it
positively as facilitating daily living. However patients
often interpreted continual use of oxygen as a failure on
their part which undermined the carers’ attempts to im-
prove functional activity inside and outside the home.
Oxygen therapy highlighted the perceived disparity be-
tween objective assessment of health status in IPF and
functional ability of patients in everyday life.
Medical management
Patients viewed pulmonary rehabilitation as positive
intervention, enabling them to participate in the man-
agement of their own disease and improve everyday
living through increased awareness of coping strategies
like energy conservation and better task management.
Carers felt these strategies were more readily accepted if
offered by a professional rather than by themselves.
Palliative care
Patients and carers frequently compared their situation
unfavourably with cancer patients whom they considered
to have “help coming from every direction”. In this context,
common misconceptions about palliative care emerged in
relation to reasons for referral as did concerns about being
referred onto “that path to death.”
Two patients had received palliative care, one in a
hospice out-patient programme and the other through
home visits. They reported significant improvement to
quality of life through peer support, and expert advice
on sleep problems, palliative medication and home
adaptations.
Roles and coping strategies of patients and carers
Patients
This study discovered significant differences in the range of
coping strategies adopted by patients and carers. Core cop-
ing strategies for patients across all four trajectories in-
cluded acceptance and adapting to change (Additional file
9: Box 8). The most significant factor for patients was
whether they lived alone or had a partner. Patients living
alone expressed their need for information about the future
course of the disease and available sources of support.
Patients with partners expressed concern about how
their partner would cope as the disease progressed.
Carers
Carers provided motivation and emotional support, pla-
cing the needs of the patient above their own (Add-
itional file 10: Box 9). They were less likely to express
positivity as a coping strategy for themselves and
expressed feelings of not being prioritised and feeling
unsure how to help. However, they did help implement
strategies such as adaptation of lifestyle and task man-
agement to conserve energy, or using oxygen. The sup-
portive role of the carer was particularly marked in the
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Extensive Progressive group, but carers across all trajec-
tories expressed fears about managing their domestic
situation in the future. Carers expressed living with feel-
ings of guilt in all trajectories. The majority of carers in
the study were female but male carers discussed how
they had adapted gender roles to cope with the changing
domestic situation as their partner deteriorated.
Discussion
This is the first qualitative study to report the support
needs of people suffering from IPF across defined
disease trajectories, as well as providing an in-depth per-
spective on the needs of their carers. The results high-
light specific opportunities to inform MDT assessments,
case mix and resource use (Fig. 1).
A striking finding of the study is the identification of
key communication strategies valued by patient and
carers. Although difficulties accessing information have
been previously described [18, 21], there has been little
exploration of the discrete preferences of patients and
carers to support practice change. By contrast, the
present study identifies three areas for improvement.
These are: to use the opportunity of clinical encounters
to focus on supportive interventions and encourage
aspects of self-management; to recognise carers as
important participants in the consultation and finally, to
appreciate that patients and carers differ in their needs
for information and that these needs change over time.
The focus of clinic consultations on disease measures
such as lung function appeared disconnected from partici-
pants’ lived experience of the disease and its impact on
everyday life. They sought a more pragmatic needs assess-
ment to include aspects of physical and social functioning,
nutrition and symptom burden to support their self-
management and guide their understanding of illness
progression. This broader assessment approach has
already been successfully employed in time pressured
clinics in other settings including cancer [22].
The requirement to better acknowledge the role and
needs of carers within outpatient consultations is an im-
portant finding. Carers described ambiguity in how they
were perceived, with negative impact on both partners’
understanding of disease course and coping strategies.
This implies a need for clinicians to change their percep-
tion of carers from passive observers to having active
roles throughout the patient pathway. It also suggests
that carers should have greater access to personal advice
and support outside clinic settings, particularly at the
time of diagnosis and during changes in health status.
An important difference between patients and carers is
the finding that, although carers maintain positivity in their
supporting role, they adopt much less positivity in coping
strategies for themselves. The carers we interviewed felt
they required a different balance in the personal support
they receive from the IPF clinic and palliative care services,
with particular attention to the social isolation and restric-
tion of lifestyle that progressive IPF brings.
CaNoPy also identifies key milestones for study partic-
ipants in their interpretation of disease progression.
Changes in health status, even when temporary, pro-
duced significant shifts in coping. Changes in function,
development of symptoms – particularly cough and
breathlessness – and instigation of oxygen represented
specific triggers for early and focused MDT support.
Whilst Swigris [5] and Schoenheit [18] reported the
impact of symptoms on health related quality of life, less
attention has been paid to timing of assessments and
triggers for intervention. In CaNoPy participants
Fig. 1 Implications for practice
Sampson et al. BMC Pulmonary Medicine  (2015) 15:155 Page 5 of 7
describe adapting to functional decline and symptom de-
velopment, assuming ever decreasing choice in lifestyle
rather than seeking assessment and support between
clinic visits. This represents lost opportunity for early
intervention in reducing symptoms and maintaining
independence, as well as for efficient resource use.
The MDT is challenged to identify systematic ap-
proaches within the care pathway which facilitate earlier
recognition of change. It underscores the need for a
broader needs assessment and presents opportunities to
examine strategies employed elsewhere, including the
roles of care trackers and emerging technologies in sup-
porting key workers [23–26].
Participants in CaNoPy who had received palliative
care support identified improvements in quality of life
by allowing them to achieve an adapted form of normal
living. Instigation of oxygen therapy was a key turning
point and an example of this type of adaptation. Whilst
carers perceived this positively as an opportunity for
maintenance of normal living, patients often felt it was
stigmatic or an intervention to be used sparingly.
Focused professional intervention at this point could
maximise benefit and reinforce the legitimacy of carer
strategies and patient involvement in self-management –
which pulmonary rehabilitation achieved for those in
receipt of it. Similarly carers appeared to take prime re-
sponsibility for management of symptoms, nutrition and
exercise. It therefore seems likely that earlier access to
palliative advice and interventions when symptoms first
emerge may provide functional benefit and reduce carer
anxiety and uncertainty.
It is well known that maintaining attitudes of positivity
and hope are important when communicating with people
suffering from IPF [19, 27, 28]. The present study extends
this notion by identifying key differences in coping strat-
egies adopted by patients at different stages of disease pro-
gression and between patients and carers. Patients in the
Limited Stable group describe difficulty managing prog-
nostic uncertainty, adopting a ‘coping day by day’ ap-
proach. Although they reported that meeting less well
patients in IPF clinics or support groups was a threat to
their ability to cope, they also felt isolated from support
between clinic visits. This has implications for frequency
of access (a suggestion that physiological stability does not
equate to less need) and the casemix of clinics, where con-
sideration is given to accommodating patients with similar
disease behaviour. Patients living alone and those with ex-
tensive, progressive disease relied on accurate, honest as-
sessment to help them plan for the future, challenging IPF
clinics to recognise triggers for advance care planning.
Limitations of this study
The clinic recruitment settings were within Wales, led
by respiratory clinicians with a specialist interest in IPF:
settings which may differ from other parts of the UK,
including potential cultural differences and different
service delivery models. Also, no patients interviewed
were receiving pirfenidone, although findings should re-
main relevant to the majority of patients with IPF.
Although a longitudinal study design might be thought
preferable, the cross sectional approach was used as the
uncertain nature of disease progression made a longitu-
dinal study difficult to achieve in the set time frame.
Conclusions
Recent guidelines have defined the need for integrated
clinical pathways in managing and supporting patients
with IPF. This study provides new evidence of perceived
gaps in the implementation of care across the disease
trajectory and highlights the needs of carers in a detail
not previously described. It suggests that in the out-
patient context, a more practical needs assessment
based on patient and carer perceptions is required,
using tools which are both relevant and applicable to
the clinic settings.
Greater consideration of clinic case mix and frequency
of appointments is required, particularly for patients
with stable disease. Clinical assessments should directly
address implications for future care planning, mindful
that patients and carers are likely to shift their expecta-
tions at different speeds.
Finally, this study highlights the importance of timing:
identifying turning points more quickly in order to trig-
ger timely assessment and intervention to improve
patient and carer outcomes. Taken together our findings
have important implications for the structure and func-
tion of IPF Clinics, multidisciplinary teams and associ-
ated clinical pathways.
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